NovaSight Announces Commercial Release of CureSight in the US; Names a New VP of Sales & Marketing

NovaSight has announced that its CureSight digital therapy for amblyopia will be released to the US market beginning this month.

CureSight received FDA 510(K) clearance based on a pivotal study that found the device to be noninferior to eye patching—the current gold standard of care—for amblyopia treatment in children. CureSight therapy is carried out while the child watches any streamed content of their choice on a user-friendly, eye tracking based device from the comfort of their home. Treatment reports are shared via a web portal allowing eye care providers to monitor patient treatment progress and compliance. 

NovaSight also announced that Drew Hopper has been appointed to Vice President of Sales and Marketing North America.

Mr. Hopper is a commercial executive leader with more than 20 years of experience in sales and marketing—including a decade in the eye care space. In the role of VP Sales and Marketing North America, Mr. Hopper will build relationships with clients; recruit key opinion leaders (KOLs) to serve on NovaSight’s scientific advisory board; support the company’s reimbursement efforts through discussions with payers; and develop, manage, and maintain sales and marketing initiatives. 

“We are excited to bring CureSight into the U.S. market, and to begin the process of building out our U.S. based commercial capabilities,” said Mr. Hopper.

A Physician Early Adopter’s Program, a dedicated CureSight Monitoring Center, and three unique CPT codes will assist U.S. eye care providers in integrating CureSight into their practices.

• Select participants in the Physician’s Early Adopter Program will begin referring CureSight to their amblyopic patients starting this month. The next step of the U.S. commercialization will commence during the first half of 2023 with an official launch that will include a group of hundreds of physicians who already signed up to the CureSight Referral Program as medical coverage scales up.
• CureSight  treatment referrals are transmitted via portal to a nation-wide Monitoring Center directed by practicing ophthalmologists and supported by a team of certified ophthalmic professionals and patient engagement specialists to provide comprehensive physician and patient support including compliance monitoring, troubleshooting, billing, and technical support.

The three unique CPT codes assigned by the American Medical Association (AMA) referred to remote treatment of amblyopia using an eye tracking device are: CPT-0704T, which is associate with device supply, initial set-up and patient education on use of the device; CPT-0705T, which is associated with monitoring-center technical support of patient activity on the device; and physicians CPT-0706T code, which is associated with physician interpretation and reporting of the data collected through the CureSight technology. These unique CPT codes mark an important step toward health insurance coverage for CureSight.

NovaSight said it is aiming to reach coverage from the top five U.S. insurance payers during 2023.